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nanocatalytic activity of clean-
surfaced, faceted nanocrystalline 
gold enhances remyelination in 
animal models of multiple sclerosis
Andrew p. Robinson1,9, Joanne Zhongyan Zhang2,9, Haley e. titus1, Molly Karl3, 
Mikhail Merzliakov2, Adam R. Dorfman2, Stephen Karlik4, Michael G. Stewart5, 
Richard K. Watt5, Benjin D. facer6, Jon D. facer5, noah D. christian7, Karen S. Ho2,8*, 
Michael t. Hotchkin2,9, Mark G. Mortenson2,9, Robert H. Miller3,9 & Stephen D. Miller1,9
Development of pharmacotherapies that promote remyelination is a high priority for multiple 
sclerosis (MS), due to their potential for neuroprotection and restoration of function through repair of 
demyelinated lesions. A novel preparation of clean-surfaced, faceted gold nanocrystals demonstrated 
robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute 
lysolecithin rodent animal models. furthermore, oral delivery of gold nanocrystals improved motor 
functions of cuprizone-treated mice in both open field and kinematic gait studies. Gold nanocrystal 
treatment of oligodendrocyte precursor cells in culture resulted in oligodendrocyte maturation and 
expression of myelin differentiation markers. Additional in vitro data demonstrated that these gold 
nanocrystals act via a novel energy metabolism pathway involving the enhancement of key indicators 
of aerobic glycolysis. in response to gold nanocrystals, co-cultured central nervous system cells 
exhibited elevated levels of the redox coenzyme nicotine adenine dinucleotide (nAD+), elevated 
total intracellular Atp levels, and elevated extracellular lactate levels, along with upregulation of 
myelin-synthesis related genes, collectively resulting in functional myelin generation. Based on 
these preclinical studies, clean-surfaced, faceted gold nanocrystals represent a novel remyelinating 
therapeutic for multiple sclerosis.
Myelination is a complex process by which axons are wrapped with oligodendrocyte (OL) membranes containing 
specialized proteins and lipids, facilitating axonal electrical conduction and providing essential trophic support 
to neurons1. During active myelination, OLs synthesize on the order of 100,000 proteins per minute2 and several 
thousand new lipid molecules per second3, reflecting the significant energetic investment needed for biomass 
generation, and making this cell type among the most energetically demanding of the body.
Dysregulated energy metabolism impacting OLs has been postulated to play a central role in MS disease pro-
gression4,5. Limited remyelination occurs in multiple sclerosis (MS) lesions despite the presence of OPCs in or 
around lesion sites. These OPCs fail to remyelinate and exhibit markers of metabolic stress6. Similarly, cultured 
human OLs, placed under metabolic stress using low glucose media, retract their cellular processes and exhibit 
significantly reduced glycolytic activity, favouring cell survival at the expense of myelin stability7,8. Under favour-
able growth conditions, human OPCs and OLs preferentially utilize aerobic glycolysis over oxidative phospho-
rylation for energy generation, resulting in an enhanced capacity to differentiate and myelinate axons7. Aerobic 
glycolysis results in production of pyruvate, acetyl coenzyme A, and NADPH, the requisite precursors of myelin 
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proteins and lipids. The enhancement of the glycolytic pathway has been proposed as a potential therapeutic 
target for remyelination in MS7.
Here we describe a new nanocatalytic therapeutic candidate for remyelination consisting of a suspension of 
clean-surfaced, faceted nanocrystals of gold. Unlike bulk gold, which does not corrode and is generally recog-
nized as chemically inert, gold at the nanoscale can be highly catalytic. Gold nanocatalysis is now widely used in 
many industrial applications9, but only recently have biologically-relevant catalytic properties of gold nanopar-
ticles been described10. One of the key reactions catalysed by gold nanoparticles is the oxidation of nicotinamide 
adenine dinucleotide hydride (NADH) to the critical energetic co-factor, NAD+11. NAD+ and NADH are not 
only metabolic sensors of cellular energy levels, but also serve as the essential redox couple for ATP-generating 
reactions, oxidative phosphorylation and glycolysis12. In addition, NADH oxidation drives cellular respiratory 
and metabolic processes that play key roles in the energetically demanding process of myelination7,8,13.
A novel electro-crystallization-based method using pure gold wire, United States Pharmacopeia (USP) grade 
water, and sodium bicarbonate results in suspensions of gold nanocrystals of 13 nm average diameter, termed 
CNM-Au8. Because this method does not require the addition of organic capping or stabilization reactants, it 
results in clean, faceted nanocrystals. The method avoids the potentially toxic deposition of organic residues on 
nanoparticle surfaces made using traditional synthesis methods14,15. CNM-Au8 exhibited significantly higher 
nanocatalytic activity than that of other commercially available comparator gold particles.
The aim of our study was to determine whether stimulation and support of energy metabolic pathways in OLs 
by gold nanocatalysis results in remyelination of axons and recovery of behavioural functions in multiple pre-
clinical models of MS. Here, we describe the efficacy of CNM-Au8 to promote the robust remyelination of demy-
elinated axons and restore motor function in in vivo animal models of MS, induce differentiation of OPCs, and 
enhance activities of neurons and OLs through enhancement of bioenergetic processes. Based on these results, 
CNM-Au8 is a viable therapeutic candidate for the treatment of remyelination failure in MS.
Results
Characterization of CNM-Au8. CNM-Au8 is a stable, aqueous suspension of gold (Au) nanoparticles in 
the shape of hexagonal bi-pyramids, pentagonal bi-pyramids, octahedrons, and tetrahedrons, as analysed by 
transmission electron microscopy (TEM). Each nanocrystal has approximately 68,000 Au atoms per nanocrystal 
with a 13 nm median diameter and a corresponding molar mass of ~1.3 × 104 kDa. The faceted structure of a 
single gold nanocrystal produced by electrocrystallization is shown in Fig. S1 and nanocrystal characteristics are 
summarized in Table S1.
Colloidal gold nanoparticles have previously been shown to catalyze the oxidation of NADH to NAD+ in a 
cell-free system11. Utilizing this UV-Vis spectrometry assay11, we demonstrated that CNM-Au8 efficiently cata-
lyzed the oxidation of NADH to NAD+ (Fig. 1a–d). Figure 1a shows the time course of the change in absorbance 
peak of NADH at 339 nm with a concomitant increase in the NAD+ peak at 259 nm. The control, sampled over 
the same time period without the addition of CNM-Au8, showed no spectral changes in NADH absorbance, 
demonstrating that NADH alone was stable and did not oxidize under these conditions (Fig. 1c, black curve). 
Furthermore, the oxidation of NADH by CNM-Au8 was dose-dependent; Fig. 1b shows NADH absorbance at 
339 nm as a function of time for four concentrations of CNM-Au8 (6.6, 12.4, 23.4, and 46.8 µg/mL). We compared 
the catalytic activity of CNM-Au8 to that of two reference standards of gold nanoparticles from the U.S. National 
Institute of Standards and Technology (NIST), 10 nm and 30 nm in diameter, respectively, at equivalent concen-
trations. Under the same reaction conditions, the nanocatalytic activity of CNM-Au8 significantly exceeded the 
catalytic activity of the citrate-reduced gold nanoparticle standards of both diameters by over 3-fold (Fig. 1c,d).
Similarly, CNM-Au8 treatment of living cells increased the intracellular NAD+ pool. Primary co-cultures of 
neural and glial cells from the mesencephalon of day 15 rat embryos were exposed to CNM-Au8, brain derived 
neurotrophic growth factor (BDNF, a control for neuroprotection), or vehicle, for 36 hours. Figure 1e demon-
strates that total cellular NAD+ levels were elevated following treatment with CNM-Au8.
The increase in NAD+ suggested that glycolytic and anabolic processes may be stimulated by CNM-Au8 treat-
ment. To measure elevated glycolytic activity, an extracellular acidification rate (ECAR) assay was used to demon-
strate the effect of CNM-Au8 treatment in OLs immediately following glucose challenge (Fig. 1f). Figure 1g shows 
that CNM-Au8 treatment of primary neuronal-glial co-cultures resulted in elevated levels of extracellular lactate, 
which is produced as a result of elevated glycolytic activity. Further, an increase in non-mitochondrial ATP pro-
duction would be expected to result from enhanced glycolytic activity. As shown in Fig. 1h, ATP derived from 
glycolytic activity significantly contributed to the enhanced levels of total ATP in CNM-Au8-treated human OLs 
compared to the vehicle controls.
Remyelination by nanocrystalline gold using the in vivo cuprizone model of demyelination. 
The copper-chelating toxin cuprizone selectively induces the apoptosis of mature OLs in the central nervous 
system (CNS) of mice following a standard treatment protocol16. With five weeks of cuprizone feeding, maximal 
demyelination of axons in the corpus callosum can be achieved, serving as a model for MS as well as other white 
matter degenerative diseases16. To determine whether CNM-Au8 had a therapeutic effect on mice exposed to 
cuprizone, CNM-Au8 was delivered to randomized groups of mice (N = 15 per group) by gavage (10 mg/kg/
day) (Groups 1–5) or was provided as their drinking water ad libitum (Groups 6 and 7). A prophylactic treatment 
arm consisted of providing CNM-Au8 to Groups 4 and 6 concomitant with the start of CPZ treatment, while a 
therapeutic treatment arm consisted of starting CNM-Au8 dosing two weeks after cuprizone administration had 
been initiated (Groups 5 and 7). Group 1 served as a non-cuprizone-treated vehicle control (sham), with vehicle 
provided by gavage daily. To assess the time-course of cuprizone damage, Group 2 was started on cuprizone and 
vehicle by gavage, then sacrificed after two weeks to verify the ongoing cuprizone insult. Group 3 was a cuprizone 
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Figure 1. Nanocatalysis by CNM-Au8 enhances cellular bioenergetics. (a) Changes in absorbance peaks 
of NADH (339 nm) and NAD+ (259 nm) demonstrate the conversion of NADH to NAD+ with time in the 
presence of 6.6 μg/mL CNM-Au8. Shown is an overlay of UV-Vis spectra taken at approximately 1 min intervals; 
total elapsed time of more than 60 minutes. Starting concentration of NADH at t = 0 was 0.08 mM. (b) Dose-
dependent catalytic activity of CNM-Au8 (6.6 μg/mL black squares, 12.4 μg/mL red circles, 23.4 μg/mL green 
triangles, 46.8 μg/mL blue triangles) on the oxidation of NADH as measured by change in absorbance of NADH 
over time. (c) Catalytic activity of CNM-Au8 compared to two NIST standards, NIST 10 nm (orange) and NIST 
30 nm (red), using the same starting concentrations: 3.4 μg/mL Au added to 26 μM NADH in 5.7 mM NaHCO3. 
No gold control (black) shows stability of 26 μM NADH during the same time frame. (d) Initial rates of catalysis 
for CNM-Au8, NIST 10 nm, and NIST 30 nm, calculated from curves shown in B. (e) Effect of CNM-Au8 
treatment on NAD+ levels, expressed as percent change over vehicle, in primary mesencephalic cultures 
compared to vehicle (grey), or BDNF control. (f) Extracellular acidification rate (ECAR) of purified murine OLs 
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and vehicle control that was sacrificed at the end of five weeks when maximal myelin damage was expected to 
have taken place16. A schematic for the study design is shown in Fig. S2.
To quantitate remyelination activity following CNM-Au8 treatment, the number of myelinated and unmy-
elinated axons in each image was counted using ImageJ (N = 587 images; average of 84 images per treatment 
group). As expected, cuprizone treatment reduced the percentage of myelinated axons compared to sham treated 
animals (Fig. 2, scatterplot p = 0.0221, two-tailed Mann-Whitney test). Striking recovery of myelinated axons 
was observed for therapeutically treated animals who were dosed with CNM-Au8 by gavage (Fig. 2, dark green 
circles). An increase in myelinated axons was also observed for animals in the prophylactic arm with CNM-Au8 
administered by gavage; however, this trend did not reach statistical significance when corrections for multiple 
comparisons were applied (Fig. 2, light green circles). Animals dosed with CNM-Au8 ad libitum also displayed 
improved myelination in TEM images (Fig. 2); however, this did not reach statistical significance.
TEM images of the corpus callosum of animals from each group were also analyzed qualitatively in a blinded 
fashion (Fig. 2). After two weeks of cuprizone treatment, significant changes in myelin morphology were noted. 
In comparison to the ordered array of well-packed and ovoid-shaped, myelinated axons in the vehicle-treated 
control (Fig. 2, “Sham”), cuprizone feeding caused extensive CNS damage: the tissue appeared disorganized, 
frequent delamination of lamellae was apparent, axons were irregularly-shaped, and patches of demyelinated 
axons were observed within areas of normal-appearing myelination (Fig. 2, “Vehicle (2 wks CPZ)” and “Vehicle (5 
wks CPZ)”). By contrast, in cuprizone-fed animals treated with CNM-Au8, there were extensive areas of normal 
myelin observed, as well as very few swollen myelin sheaths and a reduced incidence of delamination (Fig. 2).
These results corroborated those of an earlier pilot cuprizone experiment in which four groups of mice, rand-
omized by body weight (N = 4 per group), were treated with vehicle, cuprizone, CNM-Au8 alone, or CNM-Au8 
and cuprizone (Fig. S3). In this study, CNM-Au8 treated animals exhibited higher numbers of myelin-wrapped 
axons (Fig. S3b) in the corpus callosum compared to vehicle controls, and G-ratio analysis of these images 
revealed a distinct population of newly myelinated axons, (Fig. S3c). CNM-Au8 treated animals also exhibited 
higher levels of myelin proteolipid protein (PLP) expression (Fig. S3d). Taken together, these demyelinating ani-
mal model studies indicated that CNM-Au8 treatment consistently resulted in higher levels of myelinated axons 
compared to vehicle treated controls.
Remyelination by CNM-Au8 does not occur via inactivation of cuprizone. To rule out the possi-
bility that CNM-Au8’s activities are cuprizone-dependent, for example by blocking cuprizone’s copper-binding 
activity, UV-Vis spectroscopy was used to monitor binding activities of copper to cuprizone in the presence 
and absence of CNM-Au8. Copper chelation by cuprizone was characterized by an absorbance peak at 600 nm 
(Fig. S4a,b). Addition of CNM-Au8 to cuprizone alone resulted in a slight redshift in the absorbance curve 
(Fig. S4c), suggesting a weak surface interaction of CNM-Au8 with cuprizone. However, the absorbance peak of 
the copper-cuprizone saturation curve in the presence of CNM-Au8 remained unaltered at 600 nm, demonstrat-
ing uninhibited interaction of cuprizone with copper in the presence of CNM-Au8 (Fig. S4d,e). When the back-
ground signal due to CNM-Au8 alone was subtracted, the absorption spectrum of copper-cuprizone complexes 
coincided with that of copper-cuprizone without CNM-Au8, demonstrating that the presence of CNM-Au8 did 
not affect the sequestration of copper by cuprizone (Fig. S4d,e).
To assess the in vivo efficacy of CNM-Au8 once cuprizone was withdrawn, mice (N = 5 per group) were fed 
cuprizone for five weeks, then cuprizone was discontinued, and treatment with CNM-Au8 or vehicle commenced 
and continued for the following week or two weeks (Fig. 3a). Figure 3b,c show that CNM-Au8 stimulated myelin 
marker expression in OLs after cuprizone was withdrawn. The number of mature, myelin-producing OLs was 
assessed by antibody staining coronal sections from each mouse using anti-APC (CC1), a marker of mature OL 
cell bodies, and with anti-MBP, a marker of myelin-producing OLs, at the end of either one or two weeks of treat-
ment with CNM-Au8 compared with vehicle controls. As shown in Fig. 3b, the animals treated with CNM-Au8 
for two weeks following cuprizone insult showed an increase in the number of APC-positive cells in comparison 
with vehicle-treated control, which reached statistical significance for the two-week, CNM-Au8-treated group. 
This is supported by MBP immunohistochemistry results shown in Fig. 3c, in which an increase in MBP staining 
in CNM-Au8-treated mice over their respective vehicle controls is observed.
Remyelination by CNM-Au8 does not occur by direct protection of mature OLs from 
cuprizone-mediated apoptosis. Cuprizone preferentially induces the apoptosis of mature OLs over OPCs 
and other neural cell types16. To determine whether CNM-Au8 acts to protect mature OLs from apoptosis, mice 
were simultaneously treated with cuprizone and CNM-Au8 or vehicle control for two weeks during the initial 
onset of cuprizone OL toxicity, after which the animals were sacrificed and coronal brain sections were stained 
for mature OLs using anti-APC and anti-MBP antibodies (Fig. S5). Early assessment of the effects of cuprizone 
during this two-week period allowed us to detect a potential reduction in mature OL numbers before OPCs could 
differentiate and replenish the mature OL population.
in response to CNM-Au8 in the first three minutes following glucose challenge as measured in the Seahorse 
flux analyser, expressed as percent change over vehicle. (g) Extracellular lactate levels in media of primary rat 
mesencephalic cultures after 48 h treatment with CNM-Au8, expressed as percent change over vehicle. (h) Total, 
mitochondrial, and glycolytic intracellular ATP levels from human OL M03.13 cells treated with vehicle (grey) 
or CNM-Au8 (green). (d–g) One-way ANOVA, corrected for multiple comparisons. (h)Two-way ANOVA. 
Quantities shown are group means +/− SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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After two weeks of cuprizone treatment, the number of OLs marked by anti-APC and MBP was reduced in 
all coronal sections, and this reduction was not improved by concurrent treatment of CNM-Au8 or prophylac-
tic treatment of CNM-Au8 starting one week prior to cuprizone treatment (Fig. S5). This observed reduction 
Figure 2. Effect of CNM-Au8 in an in vivo cuprizone model of demyelination. Scatterplot (upper left) shows 
a quantitation of the percent myelinated axons using 16,000x TEM images by treatment group. Six of the 
seven experimental groups are shown; animals treated with cuprizone and vehicle for only two weeks were not 
quantitated. Bars show mean and SEM of each group. ****p < 0.0001, one-way ANOVA corrected for multiple 
comparisons. Representative TEM images of corpus callosum axons in cross section from sham-treated Group 
1 animals, cuprizone-treated animals sacrificed at Week 2 (“Vehicle (2 wks CPZ)”), cuprizone-treated animals 
sacrificed at Week 5 (“Vehicle (5 wks CPZ)”), cuprizone plus gavage-dosed CNM-Au8 treated animals from the 
prophylactic arm starting at week 1 (“Wk 1+”), cuprizone plus gavage-dosed CNM-Au8 treated animals from the 
therapeutic arm starting at week 3 (“Wk 3+”), cuprizone plus ad libitum-dosed CNM-Au8 treated animals from 
the prophylactic arm, and cuprizone plus ad libitum-dosed CNM-Au8 treated animals from the therapeutic arm. 
Magnifications (4000x and 16,000x) are as labelled; black scale bar = 5 μm; white scale bar = 1 μm.
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in mature OL numbers and MBP expression indicated that CNM-Au8 does not protect mature OLs from 
cuprizone-induced toxicity. Recovery of myelin following CNM-Au8 treatment in cuprizone-treated animals 
is therefore not due to the improved survival of mature OLs, but more likely due to enhanced differentiation of 
OPCs.
Effects on motor functions in cuprizone-treated mice in open-field and movement kinematic 
behavioral assays. To determine whether CNM-Au8 treatment was capable of restoring function after 
cuprizone insult, open field gross motor assessments and fine motor kinematic assessments were conducted on 
groups of mice (N = 12 per group, open field; N = 10 per group, fine motor kinetics) treated with CNM-Au8 
or vehicle. Group 1 was a non-cuprizone control with vehicle delivered to animals by gavage starting on Day 1. 
Group 2 animals were administered cuprizone and vehicle by gavage for six weeks; Group 3 was administered 
cuprizone by gavage for six weeks and CNM-Au8 for the final four weeks of the six-week study period. Behaviors 
for the open field test were assessed prior to cuprizone dosing, at the end of week 3, and at the end of week 6, while 
the fine motor kinematic tests were assessed at the end of week 3, and at the end of week 6 (Fig. 4a).
In eight of the nine quantitative behavioral parameters that were assessed in the open field test, 
cuprizone-treated animals showed statistically significant behavioral deficits from sham-treated animals by the 
end of six weeks. The ninth metric, average speed, was unchanged between cuprizone-treated and the sham 
Figure 3. CNM-Au8 promotes oligodendrocyte maturation when administered post-cuprizone treatment.  
(a) Experimental design schematic. (b) Quantitation of the number of APC positive cells by immunohistochemical 
staining of corpus callosum coronal sections from each treatment group. (c) Quantitation of the area of 
anti-MBP immunohistochemical staining of corpus callosum coronal sections from each treatment group. 
(b,c), Error bars show median and interquartile range.
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non-cuprizone treated controls, and was therefore not evaluated further. Figure 4b shows the change in each 
behavioral parameter for each group at week 6 compared to baseline as a least-square mean result. Overall, 
CNM-Au8 treatment of cuprizone-injured animals improved the performance of the mice in each of the open 
field test assays, restoring the observed cuprizone deficits versus sham treated animals, even though most individ-
ual behavioral metrics did not reach statistical significance. More specifically, we observed between 43% to 62% 
relative recovery toward sham behavior in each parameter due to CNM-Au8 treatment versus vehicle cuprizone 
treated animals (Table S2), and in all cases there was a trend in improvement towards sham. There was a statisti-
cally significant improvement in central vertical rearing counts (p < 0.05), and near-significant trends in central 
path length and vertical rearing counts (Fig. 4b).
In addition to the open field test, fine motor kinematic analyses were conducted in which parameters meas-
uring limb joint movements, posture, and gait were measured using high-speed cameras that filmed each 
mouse from multiple viewpoints (top, bottom, and side) as the animal moved. One hundred individual move-
ment parameters were measured from these videos for a quantitative assessment of gait at 3 weeks and 6 weeks 
Figure 4. Restoration of function by CNM-Au8 in open field test and fine motor kinematic analyses. (a) 
Schematic of this study design. (b) Quantitation of parameter measures from open field assessments of 
behaviour in untreated sham mice (blue bars), gavage-administered CNM-Au8 treated animals with cuprizone 
(green bars), and gavage-administered vehicle treated animals with cuprizone (red bars) expressed as a 
percentage of sham measurements at Week 6. (c) Principal component analysis of gait metrics showed no 
statistical difference (p = 0.47) between CNM-Au8 and sham treated groups as compared to a detectable 
difference in vehicle treated groups vs. sham (p = 0.032; 2-way ANOVA) by week 6. See Materials and Methods 
for statistical calculations.
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after the start of cuprizone treatment. Daily dosing of CNM-Au8 for the treated group was started at Week 3. 
Principal component analysis of these parameters, plotted as distance from sham at Weeks 3 and Week 6, is 
shown in Fig. 4c. At Week 6, the cuprizone- treated animals displayed significant gait impairment in comparison 
to the untreated sham group (−2.0 ± 0.9 units, p = 0.032 vs. sham, 2-way ANOVA). In contrast, treatment with 
CNM-Au8 largely restored kinematic movements to normal levels as the CNM-Au8-treated group became statis-
tically indistinguishable from sham-treated controls at 6 weeks (−0.67 ± 0.9 units; p = 0.468 vs. sham). Between 
week 3 and week 6, CNM-Au8-treated mice improved by 78% from their week 3 deficit relative to the sham 
controls.
Increased OL migration to lesion sites and increased myelin production by nanocrystalline 
gold following lysolecithin induced demyelination. Stereotactic lysolecithin injection is an acute, 
focal method used to induce demyelination of the spinal cord. To determine the effect of CNM-Au8 on remy-
elination in this model, the lysolecithin detergent lysophosphatidylcholine (LPC) was injected into the dorsal 
white matter of thoracic (T7) spinal cords of rats (N = 15 per group). Group 1 was therapeutically treated with 
CNM-Au8 by gavage three days post-LPC injection and Group 2 was similarly administered vehicle control. 
Animals were sacrificed for histological or immunohistochemical staining on Day 14 following LPC injection. 
Histological sections of rat spinal cords at the site of injection were stained with either Luxol Fast Blue (LFB) at 
day-7 (Fig. 5a–e) or toluidine blue at day-14 (Fig. 5f,g) to visualize myelin. LFB staining revealed the presence 
of new myelin within the site of the lesion in sections of the CNM-Au8-treated animals (Fig. 5d,e) as com-
pared to the vehicle-treated controls (Fig. 5b,c). Similarly, toluidine blue staining of spinal cord sections from 
CNM-Au8-treated animals (Fig. 5f,g) revealed a striking ‘honeycomb’ pattern of newly myelinated axons within 
the lesion site, in comparison with a lack of evidence of new myelin in vehicle-treated controls (Fig. 5g). APC 
(CC1) staining of lysolecithin-induced spinal cord lesions revealed clusters of viable, mature OLs within lesion 
sites in CNM-Au8-treated animals which were again lacking in vehicle treated controls (Fig. 5h,i).
Thinly myelinated axons, which are those with 2–4 wraps of myelin located within lesion sites, indicate axons 
undergoing remyelination post-LPC injection. A quantitation of thinly myelinated axons within lesion sites was 
conducted in a blinded fashion using TEM image analyses. The results of the quantitation are shown (Fig. 5j) 
and indicated that CNM-Au8-treated animals exhibit a 43% mean increase in myelinated axons within lesions 
post-LPC injection compared to vehicle controls. Representative TEM images clearly show evidence of remyeli-
nating axons within lesion sites of CNM-Au8 treated animals compared to vehicle controls (Fig. 5k,l).
In vitro differentiation of OPCs with treatment of nanocrystalline gold. The cuprizone and lys-
olecithin experiments suggested that CNM-Au8 either enhanced the proliferation of OPCs, or enhanced the 
differentiation of OPCs into OLs, or both. In order to address these possibilities, we utilized a flow cytometry 
OL differentiation assay17 in which OPCs were isolated18 and cultured in the presence of CNM-Au8 or vehicle. 
First, viability of OPCs in the presence of CNM-Au8 or vehicle was assessed. OPCs and differentiated OLs were 
grown in the presence of 0.06, 0.2, 0.6, and 2 µg/mL CNM-Au8 for four days and cell viability was measured using 
annexin V and propidium iodide stains to differentiate live, apoptotic, and dead cells. No change in viability of 
OPCs or OLs in response to CNM-Au8 treatment was observed (Fig. 6a).
Flow cytometry results indicated that CNM-Au8, similar to the known OPC differentiation signaling mol-
ecule triiodothyronine (T3), enhanced differentiation of mature OLs at the expense of early OPCs (Fig. 6b,c). 
OPCs were treated for four days with CNM-Au8 in growth media with (Fig. 6b,c) or without (Fig. 6d–f) the 
proliferation inducer PDGF, stained with antibodies to mark early OPCs (A2B5+/PDGFRα+) or late OPCs 
(NG2+) and then separated based on marker expression and quantitated by flow cytometry. CNM-Au8 elicited a 
clear differentiation response from OPCs when cultured in medium without PDGF (Fig. 6d–f). Flow cytometry 
based on markers for early OPCs (A2B5+/PDGFRα+), late OPCs (NG2+) and mature OLs (GALC+) showed a 
pronounced shift toward mature OLs in response to CNM-Au8 treatment, as indicated by proportionately higher 
populations of GALC + OLs in CNM-Au8-treated cultures (Fig. 6f). Immunohistochemical staining of OLs for 
MBP further confirmed not only the presence of more MBP+ OLs in response to CNM-Au8, but also that the 
terminally differentiated cells take on the morphological characteristics of differentiated OLs in the form of exten-
sive networks of processes to a similar extent and degree as the differentiation signaling molecule, T3 (Fig. 6g–i).
A second study further confirmed that CNM-Au8 stimulated the differentiation of OLs regardless of whether 
they were derived from mouse CNS or rat spinal cord cultures. Rat spinal cord cells were dissociated, cultured, 
and treated with CNM-Au8 or vehicle for 72 hours and then stained with DAPI, as well as antibodies against 
Olig2 to mark OLs and MBP to mark cell bodies and processes of mature OLs (Fig. S6).
Differential gene expression analysis of CNM-Au8-treated OPC cultures in vitro. To further char-
acterize the effect of CNM-Au8 on OPC differentiation, we conducted an in vitro RNAseq expression study using 
isolated, purified OPC cultures, with each treatment condition performed in triplicate (Fig. 7). Multidimensional 
scaling analysis was used to examine relative distances between samples according to their gene expression pro-
files. These analyses demonstrated that 1 µg/mL and 10 µg/mL CNM-Au8-treated OPC expression profiles were 
more similar to the expression profile of differentiated OLs treated with T3, than to the profile of proliferat-
ing OPCs treated with PDGF (Fig. 7a). Furthermore, CNM-Au8 treatment of mouse OPCs in primary culture 
for 72 hours results in differential expression (DE) of genes involved in myelination. Markers of OL maturation 
such as Mag, Mbp, Gjc2, Nkx6.2, and Sox10 mRNAs were elevated at least 2-fold over untreated vehicle con-
trols (Fig. 7b). Notably, there was also an enrichment of mRNA transcripts with gene ontologies related to lipid 
metabolism uniquely present in the DE gene profile for CNM-Au8-treated OPCs (Fig. 7c). These included genes 
encoding proteins involved in long chain fatty acid synthesis, which is essential to the generation of lipids that 
comprise ~70% of myelin. In contrast, the DE gene profiles for the T3 and PDGF controls did not demonstrate 
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Figure 5. Evidence of remyelination at seven and fourteen days post-lesion by CNM-Au8 treatment in a focal 
demyelination lysolecithin rodent model. Following lysolecithin lesion on Day 0, animals were sacrificed for 
histological and electron microscope analyses on Day 7 and Day 14, following daily gavage dosing of CNM-Au8 
(10 mg/kg/da) or vehicle. (a–e) Luxol Fast Blue staining of myelin in spinal cord sections of lesions at Day 7: 
from sham treated animals (a); lysolecithin lesioned, vehicle treated animals (b,c); and lysolecithin lesioned, 
CNM-Au8 treated animals (d,e), in which recovery of myelin within lesion area of CNM-Au8 treated animals 
(d,e) can be seen (grey arrowheads). (a,b,d) 10x magnification; (c,e): 20x magnification. (f,g) toluidine blue 
staining of myelin in spinal cord sections of lesions at Day 14 from vehicle (f) and CNM-Au8 (g) treated 
animals showing the distinct ‘honeycomb’ pattern of remyelination in CNM-Au8-treated animals; (f,g): 63x 
magnification. (h,i) anti-APC staining of mature OL cell bodies within spinal cord sections of lesions from 
vehicle (h) and CNM-Au8 (i) treated animals. Clusters of mature OLs can be observed in the lesion area of 
CNM-Au8 treated animals (i). (j) Quantitation of myelinated axon counts from TEM images of spinal sections 
of lesions by animal showed a 43% increase in myelination in treated animals over vehicle controls (p = 0.15, 
unpaired t-test). (k,l), Representative high resolution 100x images of spinal cord lysolecithin lesions of animals 
treated with vehicle (k) and with CNM-Au8. (l) Normal myelination, at the boundary of the lesion, can be 
observed in each panel at the upper margins of the field of view. Evidence of thinly-wrapped remyelinating 
axons are shown in (l) (encircled by yellow dashed line).
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enrichment in long chain fatty acid synthesis mRNAs. A Table of DE genes supporting the pathways in Fig. 7c 
is provided in Table S3. Taken together, these data demonstrate that treatment with CNM-Au8 promotes OPC 
differentiation and OL maturation.
Our initial bioinformatics analyses of the glycolytic, ATP-generating, and common energy metabolic path-
ways indicated that key genes known to be regulators of glycolysis/TCA cycle were not upregulated in the RNAseq 
experiment with the exception of Keap1 (Kelch-like ECH-associated protein 1), which exhibited a positive fold 
change of 1.709-fold in the CNM-Au8-treated samples over vehicle-treated samples. Transcripts corresponding to 
the Krebbs cycle rate-limiting enzyme Isocitrate dehydrogenase (Idh1), as well as known metabolic regulators of 
energy metabolism and glycolysis: Nrf2 (Nfe2I2), Prkaa1 (Ampk), Pfkfb2, Pdha1, and Pdhb, were down-regulated, 
with fold changes ranging between 0.486 to 0.914-fold. Significantly, transcripts encoding the glycolytic regulator, 
Pfkfb2 (phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2)19 showed substantial repression (0.613-fold). We 
then conducted an undirected bioinformatics approach utilizing all significant results for upregulated transcripts 
(1.2-fold or higher) using Reactome Pathway Browser20. Using this approach, we found that a highly significant 
Figure 6. CNM-Au8 mediated differentiation of immunopanned primary OPCs in culture. (a) Increasing 
concentrations of CNM-Au8 did not affect OPC or OL viability in culture. (b,c) OPCs supplemented with 
0.01 μg/mL PDGF, ‘proliferative conditions,’ do not show a proliferative response when provided with 
CNM-Au8 in the media compared to vehicle treated controls; cells expressing markers for early (b) and late (c) 
OPCs show a relative decline in numbers in response to increasing concentrations of CNM-Au8. (d–f) OPCs 
grown without PDGF, under ‘differentiation-permissive conditions,’ show a relative increase in cell numbers 
expressing the mature OL marker GALC (f), while showing a relative decrease in numbers of OPCs expressing 
early (d) and late (e) OPC markers compared to vehicle treated controls. (g–i) representative images of OPCs 
treated with vehicle (g), 0.6 μg/mL CNM-Au8 (h) and 0.04 μg/mL T3 (i) stained with DAPI to mark cell nuclei 
and anti-MBP to mark OLs expressing the mature myelin marker. OPCs treated with CNM-Au8 and cells 
treated with the positive control T3 showed higher numbers of mature OLs with complex cytoplasmic networks 
indicative of differentiated OLs.
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overrepresented upregulated pathway (p = 6.50E-04) was the Hsf1 (heat shock factor 1)-dependent transactiva-
tion pathway, with the following twenty upregulated transcripts supporting this pathway enrichment, including: 
Akt1s1, Rptor, Tnfrsf21, Serpinh1, Hspa1b, Hspa1a, Col4a6, Fkbp4, Cryab, Mtor, Camk2b, Hsf1, Ubb, Mlst8, Hspb8, 
Hspb1, Hspb2, Slc29a1, Hspa2, Dedd2. Previous studies have demonstrated that Hsf1 function resides at the nexus 
of NAD+ -associated metabolic energy regulation, cellular stress responses, and regulators of myelination (e.g, 
mTor)21. Results of this RNASeq study therefore supported the hypothesis that CNM-Au8 treatment induces an 
energetic response in OPCs, leading to the expression of myelination transcripts, albeit not directly through the 
upregulation of canonical genes associated with glycolysis, but rather through the activation of the heat shock 
factor pathway that coordinates energy metabolism, myelination22, and cellular responses to stress21.
Discussion
More than a decade of materials science and nanotechnology research has revealed unexpected catalytic prop-
erties of gold at the nanoscale. In addition to oxidation of NADH to NAD+ first characterized by Huang et al.11 
and discussed above, gold nanoparticles have demonstrated peroxidase, oxidase, catalase, and super oxide 
dismutase-like properties, all of which have significant relevance to biologic systems23,24. We now propose that a 
novel preparation of clean-surfaced faceted crystalline gold has direct therapeutic ability to support intracellular 
bioenergetic activities.
A novel electrocrystallization process that, importantly, does not involve any capping or stabilizing agents, was 
devised to grow highly faceted, pure gold crystals. This new method afforded several significant advantages: (1) 
the nanocatalytic activity of CNM-Au8 was significantly enhanced compared to that of standard citrate-reduced 
Figure 7. Transcriptomics analyses identified OL differentiation and myelination pathways that are upregulated 
in response to CNM-Au8. Isolated OPC cultures were treated with vehicle (NEUT1 and NEUT2), 1.0 (1UG1 
and 1UG2) or 10.0 μg/mL (10UG1 and 10UG2) CNM-Au8, 0.01 μg/mL PDGF to induce proliferation (PROL1 
and PROL2), or 0.04 μg/mL T3 (DIFF1 and DIFF2) to induce differentiation, for 72 h in duplicate. Cells were 
then processed for RNAseq analyses. (a) The top fifty variable genes in the dataset are displayed in the heatmap, 
with the name of each gene in each row labeled to the right. Samples were hierarchically clustered (dendrogram 
at top), demonstrating that CNM-Au8 treated cells’ transcript profiles are closer, but not overlapping, that of 
T3-treated cells, as compared to PDGF treated cells. (b) Volcano plots of differentially expressed genes, with 
the identities of upregulated genes known to play a role in differentiation and myelination indicated in red. (c), 
Gene ontology enrichment analysis revealed that gene pathways associated with myelination, plasma membrane 
regulation, and fatty acid metabolism were among those upregulated upon treatment with CNM-Au8, as well as, 
in part, with T3.
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gold nanoparticles (Fig. 1c), (2) CNM-Au8 nanocrystals were non-toxic to OPC and OL cells in culture (Fig. 6a), 
and (3) CNM-Au8 functionally improved motor behaviors in mice in vivo following exposure to the demyeli-
nating agent, cuprizone (Fig. 4). In multiple in vivo remyelination assays, treatment with CNM-Au8 significantly 
improved not only the quantifiable detection of myelinated axons in the brains of experimental animals, but also 
mouse behaviors and functional movements in the open field test and kinematic assays. In contrast, the necessary 
addition of capping and surfactant agents in order to generate and stabilize nanoparticles made using traditional 
methods can introduce adverse, cytotoxic effects in biological systems15.
The currently available FDA-approved drugs for the treatment of MS act to suppress the recurrent autoim-
mune attack on myelin during disease progression. These drugs generally limit disease progression by reducing 
the frequency and intensity of autoimmune attacks. A remyelinating therapy, acting in concert with, or inde-
pendently of, immunosuppressant drugs, opens up the possibility of restoration of functions that were previously 
impaired or lost due to MS disease activity, thereby improving patients’ quality of life and potentially reversing 
disease progression.
CNM-Au8 appears to act through a novel nanocatalytic mechanism through a pathway involving the ener-
getic coenzymes NAD+ and NADH. These metabolites are vital for driving cellular reduction-oxidation (redox) 
reactions in living cells, including both glycolytic and oxidative phosphorylation pathways of energy generation. 
In addition to its redox role, NAD+ acts as a substrate for key regulators of metabolism and repair25. NADPH is 
generated from NAD+, and is required for anabolic pathways including the synthesis of long chain fatty acids 
that are required not only for myelin production, but also to protect cells from reactive oxygen species (ROS)26.
A NAD+ deficiency of more than 50% has been detected in the serum samples of MS patients compared to 
healthy controls27. Intriguingly, this NAD+ deficiency increases amongst MS subgroups with increasing severity 
of the disease27. NAD+ has been proposed to be a potential therapeutic target for MS treatment27–29.
OPCs present in MS lesions are thought to be unable to remyelinate because they have undergone cellular 
stresses that have led to their bioenergetic failure (3). CNM-Au8 may catalytically compensate for intracellular 
energy loss, stimulating OPC differentiation and accelerating myelination28,29.
Many neurodegenerative diseases share hallmarks of energy depletion, mitochondrial dysfunction, and met-
abolic stress in multiple central nervous system cell types prior to clinical symptom onset30. Because the mech-
anism of action of CNM-Au8 is not limited to a single protein target or cell type in the CNS, the applicability 
CNM-Au8 as a neurotherapeutic is potentially wide-ranging and highly applicable to those neurodegenerative 
diseases impacted by impaired cellular bioenergetics. Preclinical studies investigating the therapeutic potential 
of CNM-Au8 for the treatment of Parkinson’s disease, amyotrophic lateral sclerosis, and other complex neurode-
generative diseases are presently underway.
There are limitations to this study. While we demonstrated an improvement in open field and fine motor 
behaviors in response to CNM-Au8 in cuprizone-treated mice, many of the individual parameters measured did 
not reach statistical significance distinct from the cuprizone-treated controls (Fig. 4). Post-hoc sample size cal-
culations based on the observed differences between the Group 1 (sham) animals and the Group 2 (vehicle plus 
cuprizone-treated) animals indicated that significantly more animals would be needed to detect significant treat-
ment effects on individual parameters. Cuprizone itself does not consistently demyelinate brain areas uniformly 
when evaluated both on a within-animal and a between-animal basis31; therefore the toxin’s effects, particularly if 
mild, can be difficult to demonstrate on a quantitative basis. Nevertheless, remyelination due to CNM-Au8 treat-
ment was reproducibly demonstrated in the four cuprizone and the lysolecithin models presented herein, when 
evaluated on ultrastructural, cellular, and functional levels. The observed functional and gait improvements with 
oral administration of CNM-Au8 therefore warrants further study.
In addition to the preclinical efficacy studies of CNM-Au8 as a potential remyelinating therapeutic for MS 
described here, the drug development program for CNM-Au8 included IND-enabling toxicology studies as well 
as a First-in-Human Phase I study (NCT02755870). The results of the genotoxicity, safety pharmacology, and 
acute and chronic toxicology studies for six months’ duration in rodents and nine months’ duration in canines 
indicated a clean safety profile for CNM-Au8, with no severe adverse effects identified in any of these studies even 
at the highest maximum feasible doses tested.
Notably, the blood brain barrier penetrance of CNM-Au8 was demonstrated as part of these chronic toxic-
ity studies by determining the concentration of CNM-Au8 in the spinal cord and brain of canines dosed with 
CNM-Au8 by oral gavage for nine months. Quantitation of CNM-Au8 in organs and tissues is confounded by 
the presence of naturally-occurring background levels of gold. Nevertheless, quantitation by inductively coupled 
plasma mass spectroscopy demonstrated significantly more animals with CNS gold levels greater than the limit 
of detection in the spinal cord, CSF, and brains when dosed with CNM-Au8 by gavage daily compared to vehicle 
controls. Therefore, orally delivered CNM-Au8 is blood brain barrier penetrant, albeit at low levels.
Due to promising preclinical data described here and the favorable safety/toxicity profiles achieved by 
CNM-Au8, a Phase 2, double-blinded, randomized, placebo-controlled study, VISIONARY-MS (Treatment 
of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability, and 
Pharmacokinetics of CNM-Au8 For Remyelination In Stable Relapsing Multiple Sclerosis (RMS) is currently 
underway. This clinical study is designed to assess remyelination through a functional vision improvement pri-
mary endpoint, change in low contrast letter acuity, and a secondary electrophysiologic endpoint of improvement 
in multi-focal visual evoked potential latency in the affected eye. These endpoints have been employed in previous 
clinical trials for the assessment of remyelinating activity32–34. Results from VISIONARY-MS are expected in 2021.
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Methods
Animal care and husbandry. Animal studies were approved by the respective Institutional Animal Care 
and Use Committees at Charles River Labs (Kuopio, Finland) and Northwestern University Feinberg School 
of Medicine, and conducted with adherence to the NIH Guide for the Care and Use of Laboratory Animals. 
Animals were housed under pathogen–free conditions with food and water provided ad libitum. C57BL/6 mice 
and Sprague-Dawley rats were used in all experiments.
Vehicle and CNM-Au8. The vehicle used was 6.5 mM NaHCO3.
The processes for production of CNM-Au8 have been described (US Patent 9,603,870)35. In brief, water con-
taining NaHCO3 at a 6.5 mM concentration was transferred to an electrochemical processing device through 
which the buffered water flowed at a constant rate. The buffered water was exposed to an electrical plasma gen-
erated between a gold electrode, suspended above the water, and the surface of the buffered water, which sur-
face functioned as a second electrode to generate “conditioned water.” The conditioned water was subsequently 
exposed to a series of paired gold wire electrodes. Each gold wire electrode pair was held by a controller that 
advanced the electrode pairs through the conditioned water with continuous application of alternating current 
as the conditioned water flowed past each electrode pair. The resulting gold nanocrystal suspension was sub-
sequently concentrated, filtered with an antimicrobial filter, then filled into single unit HDPE containers. All 
processes were executed in a clean room. Each batch of CNM-Au8 was analytically assayed (Table S1) to ensure 
release specification standards were met.
cell-free nADH oxidation assays. UV-Vis spectroscopy was conducted as described11. Citrate-reduced 
30 nm and 10 nm gold nanoparticles were acquired from the National Institute of Standards and Technology.
In vitro quantitation of nAD+ and nADH. Primary rat mesencephalic neural-glia co-cultures were 
seeded at a density of 40,000 cells/well in 96-well plates pre-coated with poly-L-lysine36. After four days of cul-
ture, CNM-Au8 (10 ng/mL, 100 ng/mL, 1 µg/mL, 10 µg/mL), BDNF (50 ng/mL), or vehicle was added for 36 h. 
Quantitation of NAD+ and NADH was performed by bioluminescent assay (Promega kit #G9071).
In vitro quantitation of Atp. M03.13 cells (TebuBio) were seeded at a density of 20,000 cells/well in a 
96-well plate. After one day of culture, cells were treated with CNM-Au8 (0.1 µg/mL, 0.32 µg/mL, 1 µg/mL) or 
vehicle for 72 h. Half of the wells (N = 3 per condition) were treated with mitochondrial blockers (100 µM anti-
mycin A, 0.5 µM rotenone, 3 µM oligomycin) for two hours. Wells were then lysed in luciferase buffer. ATP was 
determined by bioluminescence assay (1 s integration time, CLARIOstar). Mitochondrial ATP was calculated by 
subtracting the average ATP level from mitochondria-blocked cells from average total ATP levels of untreated 
cells.
Extracellular acidification rate (ECAR) measurements. OPCs from P7 mouse pups were immuno-
panned and seeded in 96-well plates in OPC optimal medium18. CNM-Au8 (0.3 ng/mL, 1 ng/mL, 3 ng/mL, 10 ng/
mL) or vehicle was added to the culture for 24 h. ECAR was measured using the Seahorse flux analyser (Agilent). 
Protein content was determined by Bradford (BioRad). Experiments were performed in triplicate.
cuprizone treatment. The 5-week cuprizone demyelination model has been described16. Male mice 
(Taconic Farms, 8 weeks old) were assigned to one of seven groups, balanced by weight, N = 15 animals in each 
group. 0.2% cuprizone chow and normal control chow were obtained from Harlan Laboratories (Bethesda, MD). 
Groups 1–5 were dosed with vehicle (6.5 mM NaHCO3 at 10 mL/kg by gavage daily) or CNM-Au8 (10 mg/kg/day) 
by gavage at the same time (+/− 1 hour) each day. Cuprizone treatment started on Day 0 for all groups except 
control Group 1, which was fed normal chow. Prophylactic dosing was started on Day 0 (Groups 1–4 and Group 
6). Therapeutic dosing started on Day 14 (Groups 5 and 7). Group 2 mice were sacrificed on Day 14; all other 
groups were sacrificed on Days 34–36.
For the post-cuprizone CNM-Au8 treatment study, twenty-five 8-week old, male mice were divided by weight 
into five groups. For treatment schematic for each group, see Fig. 2a.
corpus callosum sectioning and teM imaging. Two 2 mm sagittal slices of brain tissue on either side 
of the midline containing the posterior corpus callosum were dissected and processed for TEM imaging37 from 
mice from each treatment group. Imaging was carried out at 4000x, 16,000x, and 40,000x using Zeiss Libra 120 
transmission electron microscope.
coronal brain sectioning, fixing, immunohistochemical staining and quantitation of sig-
nal. 10 µm coronal mouse brain sections containing the corpus callosum (10 per animal) from each treatment 
group were prepared for immunohistochemical staining as described38. Sections were blocked with donkey serum 
and stained with 5 µg/ml MBP (Abcam, ab40390) or 1 µg/ml APC (Abcam, ab15270) overnight at 4 °C, washed 
in PBS, then stained with AlexaFluor 488 or AlexaFluor 594 (Millipore, 1:500), and counterstained with Hoechst. 
Imaging was done on a Nikon A1R+ confocal microscope. Post-image analysis of 8 sections per animal was con-
ducted using ImageJ39.
Qualitative assessment of teM images. Analyses of 3000 TEM images (4000x, 13,500x, 16,000x, and 
40,000x) from 85 mice (10–15 animals per treatment group) were carried out by a pathologist blinded to the 
treatment group.
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Quantitation of myelination. TEMs of corpus callosum images at 16,000x magnification: N = 587 images 
total; 70 images from Group 1 (N = 7 animals), 110 from Group 2 (N = 15 animals), 79 from Group 3 (N = 8 
animals), 94 from Group 4 (N = 9 animals), 90 from Group 5 (N = 9 animals), 53 from Group 6 (N = 7 animals), 
and 91 from Group 7 (N = 7 animals) were analysed using ImageJ39 to count the number of myelinated and 
unmyelinated axons in each image. The percentage of myelinated axons per image was then calculated. G-ratios 
were calculated as the inner myelin circumference divided by the outer myelin circumference. Analyses were 
conducted by investigators blinded to treatment group.
Lysolecithin demyelination model. The demyelinating lysolecithin lesion model has been described40. 
Animals were allowed to recover for 7 or 14 days prior to analysis. Vehicle (N = 15 rats) or CNM-Au8 (N = 15) 
was administered by gavage daily (10 mg/kg/day) starting on day 3 following lysolecithin injection. Animals were 
sacrificed on day 7 or day 14. Lesioned areas were sectioned and stained for myelin using Luxol fast blue or tolui-
dine blue. Quantitation of myelinated axon counts was conducted on TEM images of lesion sections by manually 
counting the number of thinly-wrapped (2–4 wraps) axons within lesion boundaries, in blinded fashion.
Open field and fine motor kinematic studies. Open field (N = 12 mice/group) and fine motor kine-
matic (N = 10 mice/group) analyses of cuprizone/CNM-Au8 treated animals were performed by Charles River 
Laboratories (Kuopio, Finland).
For the open field test, mice were placed in the centre of an activity chamber equipped with infrared beams 
(Med Associates, Inc.). Behaviours were recorded for 30 min in 5-min bins.
Fine motor skills and gait parameters were assessed using an automated, high precision kinematic analysis 
system (MotoRater, TSE Systems). Before each test session, mice were externally marked on joints of limbs and 
tail. Movements were captured using high speed (300 fps) cameras positioned above, below, and at the side of the 
animal and analysed using SimiMotion and custom software (Charles River Labs).
Proliferation/differentiation assays of OPCs by flow cytometry. OPCs from stage P5-7 C57BL/6 
mouse pups were immunopanned18, then grown in media supplemented with 0.01 μg/mL PDGF or 0.04 μg/mL 
T3 and treated with vehicle or CNM-Au8 for 72 hours. Flow cytometry was performed as described17.
RnASeq transcriptomic expression assay. OPCs from stage P10 C57BL/6 mouse pups were immuno-
panned18, then treated with vehicle, 0.04 μg/mL T3, 0.01 μg/mL PDGF, or 1 μg/mL or 10 μg/mL CNM-Au8 for 
72 hours. Two technical replicates were conducted for each condition.
RNAseq libraries were prepared from treated OPCs, then sequenced (Illumina Hiseq. 4000). Reads were 
aligned using STAR; gene counts were computed by htseq-count. Downstream analyses were performed using 
R, with the limma, edgeR, TopGO Bioconductor packages. Heatmaps were plotted using the gplots R pack-
age. Bioinformatics analyses were also conducted using Reactome Pathway Browser20. Pathways that were 
over-represented using the set of DE genes that were significantly upregulated (1.2-fold or higher) or downreg-
ulated (0.8-fold or lower) were analysed for relevance to energy metabolism, redox regulation, and myelination.
Statistical methods. Unless described below, statistical analyses were carried out using MS Excel package 
and/or Prism 7.0. Statistical significance was defined as p values of 0.05 or less.
Open field parameters analysis. Three time points (Baseline, Week 3, Week 6) associated with each of six parame-
ters (Path Length, Central Path Length, Vertical Rearing, Central Vertical Rearing, Jump Counts, and Jump Time) 
were analysed. Mixed model repeated measures (MMRM) was used to test for treatment differences (change from 
baseline). Covariates consisted of baseline score of each parameter and baseline weight. An unstructured covari-
ance model was used to account for correlated measures within a subject. The Kenward-Roger method was used 
to compute degrees of freedom for the test of fixed effects. Least-square (LS) means and 95% confidence interval 
(CI) for each treatment and time point were calculated to account for the unbalanced data of the main effects and 
covariates. Comparisons of treatment groups were taken as the difference of the LS means.
Mouse motor kinematics. Ten principal components (PC) of gait features (Slowness, Tail Tip Height, Knee 
Function, Step Length, Interlimb Coordination, Vertical Movement, Hip Angle, Hindlimb Trajectory, Hip Height, 
Forelimb Trajectory) were identified from ~100 kinematic gait parameters collected. Each PC encompassed the 
results for 2 timepoints, Week 3 and Week 6.
To test for treatment differences, MMRM analyses were used in the same manner described above. 
Comparisons of treatment groups were taken as the difference of the LS means.
Data availability
CNM-Au8 must be obtained through an MTA. All data associated with this study are available in the main text 
or the Supplementary Materials.
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